HIGHLIGHTS
- who: Paolo Alimonti and L. Nicolas Gonzalez Castro from the Department of Medicine, Vita-Salute San Raffaele University, Via Olgettina, , Milano, Italy have published the research work: The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors, in the Journal: Antibodies 2023, 27 of /2023/
- what: This study provided evidence in support of the neoadjuvant use of PD-1 inhibition in progressive GBM, which is yet to be validated in larger studies. Four studies evaluated PD-1 inhibitors, including camrelizumab, sintilimab, and tislelizumab, alone or combined with other chemo-immunotherapy agents . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.